Information Library

Results for: Cardiovascular - Phase II/III

To learn more about Quintiles’ services, you may broaden or narrow your search by selecting the topics at left.

Start Over

  • Sort by:
  • Recently Added
  • Title

  • Constant Vigilance

    Case Study — March 16, 2011
    Centralized planning played a key role in improving productivity during site visits and close monitoring ensured the high standards Quintiles put in place were met.

  • Clinical – Smarter Trials, Accelerated Outcomes

    Brochure — February 16, 2011
    Quintiles will work with you to plan and execute the smartest clinical trials and post-marketing studies, informed by a holistic view of strategic, operational, regulatory and marketplace issues.

  • Acute Coronary Syndrome - Tailored Solutions

    Case Study — February 1, 2011
    Find out how our experience in multi-national cardiovascular clinical trials helped this customer reach database lock 66 days after LPO.

  • Exclusive Report From Scientific American

    Hear from the Experts — November 9, 2010
    In-depth insights on every angle of the changing health landscape - brought to you by Quintiles Get the report today.

  • Regulatory Landscapes for Future Antidiabetic Drug Development

    Hear from the Experts — May 12, 2010
    In the March 2010 Journal for Clinical Studies, Dr. Erica Caveney and Dr. Rick Turner analyze the EMA Guidance on diabetes drugs and cardiovascular risk.

  • EMA’s Guidance on New Antidiabetic Drug Development

    White Paper — May 12, 2010
    Assessing the EMA’s Guidance on New Antidiabetic Drug Development In January 2010, the European Medicines Agency (EMA) issued a draft guideline on antidiabetic drug development

  • Trumping Expectations

    Case Study — March 1, 2010
    Quintiles sails past recruitment hurdles with tailored approaches that build momentum

  • Journal for Clinical Studies

    Hear from the Experts — February 19, 2010
    In the January 2010 Journal for Clinical Studies, Dr. Erica Caveney and Dr. Rick Turner analyze the FDA Guidance on diabetes drugs and cardiovascular risk.

  • New FDA Guidance on Antidiabetic Therapies

    White Paper — December 11, 2009
    Understanding the FDA Guidance on Assessing Cardiovascular Risks for new Antidiabetic Therapies. Learn what FDA cardiac safety requirements may mean for your development program.

  • Sub-Saharan Africa Phase II/III Fact Sheet

    Brochure — July 29, 2009
    Sub-Saharan Africa fact sheet about Phase II/III trials. The gateway to Africa: Access to expanded clinical resources and patient populations in South Africa and beyond.

Page 1 of 2 (11 results)

Subscribe to Email Based on Your Interests

Set preferences